[go: up one dir, main page]

MX2023015245A - Pirimidinil-pirazoles sustituidos como inhibidores de cdk2. - Google Patents

Pirimidinil-pirazoles sustituidos como inhibidores de cdk2.

Info

Publication number
MX2023015245A
MX2023015245A MX2023015245A MX2023015245A MX2023015245A MX 2023015245 A MX2023015245 A MX 2023015245A MX 2023015245 A MX2023015245 A MX 2023015245A MX 2023015245 A MX2023015245 A MX 2023015245A MX 2023015245 A MX2023015245 A MX 2023015245A
Authority
MX
Mexico
Prior art keywords
pyrazoles
substituted pyrimidinyl
cdk2 inhibitors
cdk2
inhibitors
Prior art date
Application number
MX2023015245A
Other languages
English (en)
Inventor
Douglas Wilson
Steven Mark Wenglowsky
Natasja Brooijmans
Richard Vargas
Philip D Ramsden
Jr Neil Bifulco
Emanuele Perola
Original Assignee
Blueprint Medicines Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blueprint Medicines Corp filed Critical Blueprint Medicines Corp
Publication of MX2023015245A publication Critical patent/MX2023015245A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente descripción proporciona un compuesto representado por la fórmula estructural (I): (ver Fórmula) (I), o una sal farmacéuticamente aceptable de este útil para tratar el cáncer.
MX2023015245A 2021-06-16 2022-06-15 Pirimidinil-pirazoles sustituidos como inhibidores de cdk2. MX2023015245A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163211426P 2021-06-16 2021-06-16
US202263327474P 2022-04-05 2022-04-05
PCT/US2022/033576 WO2022266190A1 (en) 2021-06-16 2022-06-15 Substituted pyrimidinyl-pyrazoles as cdk2 inhibitors

Publications (1)

Publication Number Publication Date
MX2023015245A true MX2023015245A (es) 2024-01-19

Family

ID=82694316

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023015245A MX2023015245A (es) 2021-06-16 2022-06-15 Pirimidinil-pirazoles sustituidos como inhibidores de cdk2.

Country Status (16)

Country Link
US (1) US20240287040A1 (es)
EP (1) EP4355742A1 (es)
JP (1) JP2024523892A (es)
KR (1) KR20240022609A (es)
AU (1) AU2022293861A1 (es)
BR (1) BR112023026538A2 (es)
CA (1) CA3224189A1 (es)
CL (1) CL2023003758A1 (es)
CO (1) CO2024000221A2 (es)
CR (1) CR20240014A (es)
DO (1) DOP2023000277A (es)
EC (1) ECSP24003566A (es)
IL (1) IL309013A (es)
MX (1) MX2023015245A (es)
PE (1) PE20240769A1 (es)
WO (1) WO2022266190A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117715904A (zh) 2021-05-07 2024-03-15 凯麦拉医疗公司 Cdk2降解剂和其用途
KR20240046167A (ko) 2021-06-28 2024-04-08 블루프린트 메디신즈 코포레이션 Cdk2 저해제

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06007820A (es) * 2004-01-09 2006-09-01 Novartis Ag Derivados de fenil-[4-(3-fenil-1h-pirazol-4-il)-pirimidin-2-il]-amina como inhibidores de igf-ir.
CA2987552A1 (en) * 2015-06-04 2016-12-08 Aurigene Discovery Technologies Limited Substituted heterocyclyl derivatives as cdk inhibitors
WO2020205560A1 (en) * 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors

Also Published As

Publication number Publication date
WO2022266190A1 (en) 2022-12-22
AU2022293861A1 (en) 2024-01-04
US20240287040A1 (en) 2024-08-29
ECSP24003566A (es) 2024-04-30
JP2024523892A (ja) 2024-07-02
IL309013A (en) 2024-01-01
CO2024000221A2 (es) 2024-01-25
CR20240014A (es) 2024-05-07
KR20240022609A (ko) 2024-02-20
BR112023026538A2 (pt) 2024-03-05
DOP2023000277A (es) 2024-03-28
PE20240769A1 (es) 2024-04-17
EP4355742A1 (en) 2024-04-24
CA3224189A1 (en) 2022-12-22
CL2023003758A1 (es) 2024-07-12

Similar Documents

Publication Publication Date Title
PH12022551574A1 (en) Egfr inhibitors
MX2024000230A (es) Inhibidores de cdk2.
PH12021552805A1 (en) Cdk inhibitors
MX2023000025A (es) Inhibidores de la quinasa progenitora hematopoyética 1 y usos de estos.
PH12020500673A1 (en) Compounds
ZA202206923B (en) New methylquinazolinone derivatives
MX2021000348A (es) 2-fluoro-3-nitrotolueno cristalino y procedimiento para la preparacion del mismo.
MX2023015245A (es) Pirimidinil-pirazoles sustituidos como inhibidores de cdk2.
EA201792320A1 (ru) Способ лечения рака ингибитором пути stat3 и ингибитором киназы
CR20240147A (es) Uso de un inhibidor de la ezh2 en la preparación de fármacos para el tratamiento del linfoma de linfocitos t
PH12021552787A1 (en) Tetracyclic compounds as cdc7 inhibitors
ZA202205170B (en) Process and intermediate for the preparation of oxetan-2-ylmethanamine
ZA202213318B (en) Antifungal agent for use in humans
UY39662A (es) Inhibidores de egfr
MX2022001044A (es) Inhibidor de sglt2/dpp4 y su aplicacion.
MX2023015126A (es) Compuestos y metodos para tratar la hiperpotasemia.
MX2021015418A (es) Terapia inmunooncologica.
PH12021550248A1 (en) Borate of azetidine derivative
EA202193248A1 (ru) ТЕТРАЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Cdc7